An actin-binding protein filamin A connects the actin filament network to cell membrane receptors, and acts as a scaffold for various signaling pathways related to cancer growth and progression. Recently, it has been reported that filamin A is required for efficient regulation of early stages of DNA repair process. Moreover, some in vitro studies showed that the overexpression of filamin A determines resistance to various cytotoxic drugs, including cisplatin. We aimed to analyse the expression of filamin A protein in resected NSCLC (Non Small Cell Lung Cancer) specimens, to investigate the association of the level of filamin A protein expression and other clinicopathological features, and possible relationship between the expression of filamin A and survival outcome in NSCLC patients, treated with platinum-based combination chemotherapy. We performed filamin A protein immunohistochemistry on formalin-fixed and paraffin-embedded (FFPE) tissue sections from 135 NSCLC patients, using EP2405Y antibody against C-terminus of filamin A. Cytoplasmic, membranous and nuclear positivity of filamin A was evaluated semi-quantitatively and correlated with available clinicopathological data. Patients were divided into two groups for survival analysis (I group -patients treated with adjuvant platinum-based chemotherapy, II group -patients with surgical treatment only). We found significant positive correlation between filamin A protein expression and NSCLC stage (r=0.249; p<0,05), presence of lymph node (N)(r=0.205; p<0,05) and distant metastases (M) (r=0.332; P<0.01). Increased filamin A protein expression was significantly related with poor survival outcomes in patients with adjuvant platinum-based chemotherapy: OS (HR=1.005, 95%CI[1.000;1.010], p=0.037), DFS (HR=1.004, 95%CI [1.001:1.008], p=0,017). Multivariate Cox proportional hazards regression analysis also showed that overexpression of filamin A represents an independent risk factor for disease relapse, in addition to tumor size, stage, and metastases status (HR=1.723, 95%CI [1.021:2.909], p<0.05). Thus, filamin A expression might be a new prognostic marker in patients with NSCLC.
Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases and represents the leading cause of cancer related mortality worldwide [1] . The most favourable outcome in patients with resected NSCLC in stage IB-III has been shown after platinum-based chemotherapy. However, the improvement of survival rate using this type of chemotherapy was only ~5% [2] . In the majority of cases, treatment efficacy is markedly reduced by intrinsic or acquired chemoresistance. Mechanisms of resistance to platinum-based compounds, such as cisplatin and carboplatin are complex and numerous, including the highly efficient DNA damage repair [3, 4] . According to recent experimental studies, filamin A has emerged as one of the key proteins involved in the DNA damage response.
Filamin-A (also known as human actin-binding protein 280 (ABP-280) or filamin-1), is a cytoskeletal protein involved in 16q22.1 LOSS AND RECURRENCE RISK IN HCC regulation of cell shape and locomotion. The primary function of filamin A protein is to cross-link actin filaments into orthogonal networks and assist the formation of cytoskeleton. Filamin A also connects actin networks to plasma membrane and facilitates cell-matrix interactions. This aside, filamin A interacts with more than 60 non-cytosceletal proteins related to cancer growth and metastasis and, serves as a scaffold for various signaling pathways [5] . A number of studies report different levels of filamin-A expression in cancer tissue, compared to healthy tissue. Increased expression of filamin-A has been found in colorectal [6] ], pancreatic [7] , hepatic [8] and breast [9] carcinomas, whilst there is a marked decrease of filamin-A expression in human bladder [10] and nasopharyngeal [11] cancer.
Recently, it has been shown that filamin A protein plays an essential role in earlier stages of DNA repair via interaction with BRCA1 and BRCA2 in vitro [12, 13] . The overexpression of filamin A determines resistance to various cytotoxic drugs, including bleomicin and cisplatin in melanoma cell lines and mouse xenograft models [14] . Also, A2780 epithelial ovarian cancer cell line, with acquired platinum resistance, shows markedly increased levels of filamin A mRNA [15] . These experimental data suggest the potential role of filamin A protein expression as a marker of DNA damaging chemotherapy response, however the clinical relevance of this information is lacking.
The aim of this study was to analyse the expression of filamin A protein in resected NSCLC specimens, to investigate the association of the level of filamin A protein and other clinicopathological features as well as possible relationships between the expression of filamin A and survival outcome of patients treated with platinum-based combination chemotherapy. of the study were determined as overall survival (OS) and disease-free survival (DFS). OS was defined as the period from the date of surgery until death or to the last date of follow-up; DFS was defined as the period from the date of surgery to the date of relapse or metastasis. Cases lost during follow-up and those ending in death from any cause other than lung cancer were regarded as censored data in the analysis of survival rates. Median follow-up was 38 months (range 2 -181 months). Detailed clilnicopathological characteristics of patients and tumors are given in Table 1 .
Patients and methods

Patient
Immunohistochemical staining. Sections (4 μm) from formalin-fixed and paraffin-embedded (FFPE) tissue samples were used and stained by using Ventana Benchmark XT automatic tissue stainer from Roche. The monoclonal EP2405Y antibody against C-terminus of filamin A (LSBio) was used in dilution 1:500. Tissue sections without primary antibody addition and served as a negative control. Normal skin tissue was used as a positive control. The stained slides were blindly evaluated by two pathologists (M.G, J.Š). Membranous cytoplasmic staining was assesed by the histoscore method (percentage of positive cells x intensity of staining -1, weak; 2, moderate; and 3, strong). The final histoscore ranged from 0 (minimum) to 300 (maximum)). Non-representative, dam- 
Results
Immunohistochemical expression of filamin A was characterized with marked variability in NSCLC, as well as in lung tissue surrounding the tumor. Bronchial columnar epithelial cells exhibited mainly moderate apical cytoplasmic and membranous staining, and relatively intensive staining in the attachment to the basal membrane. Submucosal glandular cells exhibited weak membranous positivity ( Figure 1A ). Bronchiolar connective tissue was either negative for filamin Figure 1A,B) . Chondrocytes in bronchiolar cartilage were strongly positive ( Figure 1C ). Type I pneumocytes showed weak to moderate cytoplasmic and membranous positivity ( Figure 1B) . NSCLC tissue showed weak to strong cytoplasmic and/or membranous expression of filamin A with marked intratumoral variability. Nuclear staining was present only in 6 cases. Tumor stroma was always moderately or strongly positive ( Figure 1D ) and was served as internal positive control for filamin A negative tumors. Filamin A expression was relatively high in the peripheral parts of tumor tissue, compared to central parts of solid tumors ( Figure 1E,F) . There was no significant difference in filamin A expression between different histological subtypes of NSCLC ( Figure 3A) . Some typical staining patterns are given in Figure 1 (G-I). IgG controls and matched NSCLC tissue staining are given in Figure 2 .
After exclusion of non-representative, damaged or nonevaluable cases, 99 NSCLC patients were included in final statistical analysis. The comparison of filamin A expression in different clinico-pathological groups showed that, the highest expression of filamin A is characteristic for grade 2 tumors, followed by grade 3 and grade 1 tumors (p<0.05, Figure 3B ). Filamin A expression was positively associated with tumor size and invasion (T), particularly it was significantly higher in T3-4 tumors, compared to T1-2 tumors (p<0.01, Figure 3C ). Also, filamin A expression was higher in patients with lymph node (N) and distant metastases (M) (p<0.05, Figure 3E,F) . Overall, filamin A cytoplasmic and membranous expression was significantly higher in stage IV disease, followed by stage III and stage I-II (p<0.01, Figure 3D ). Spearman's rank test also showed a significant positive correlation between filamin A expression and NSCLC stage (r=0.249; P<0.05), lymph node metastases (N) (r=0.205; P<0.05) and distant metastases (M) (r=0.332; P<0.01).
Based on univariate Cox proportional hazards regression model, patients within our cohort were divided into low and high risk groups according to filamin A expression, <=90 and >90 respectively. Particularly, the risk of tumor recurrence was significantly higher in patients with high (>90) filamin A expression, compared to patients with low (<=90) expression, despite the treatment (HR=1.003 95%CI[1.000:1.005], P=0.02, Figure 4 . B). The risk of death was also higher in patients with >90 filamin A expression (HR=1.003 95%CI [1.000:1.005], P=0.07, Figure 4) Figure 5 . The quantitative distribution of filamin A expression in different clinicopathological groups is given in Table 2 .
Discussion
We found that filamin A expression is characterised by marked inter and intratumor variability in NSCLC. The strongest expression was observed in the peripheral parts of solid tumors and the expression of filamin A significantly correlated with primary tumor size and, the presense of lymph node and distant metastases. These findings suggest an important role of filamin A in NSCLC growth, invasion and metastases. Evidence for the role of filamin A in tumor progression is controversial in published literature. Some studies report that inhibition of filamin-A reduces cancer metastatic potential, [16] . Also, it has been shown that the targeting of filamin A results in significant decrease in size and invasive potential of lung cancer in mice [17] . In clincial studies, a positive relationship between overexpression of filamin-A protein and advanced stage, lymph node metastasis and vascular or neural invasion has been seen in breast and colorectal cancer patients [9] , whilst the opposite was shown in nasopharingeal cancer [11] . This might be explained by the individual nature of each tumor. Our second finding that filamin A protein represents an additional prognostic factor in NSCLC patients is supported by the multivariate Cox regression analysis, which showed that the overexpression of filamin A (>90) is a negative prognostic factor together with tumor size, disease stage and nodal status (HR=1.723, 95%CI [1.021:2.909], P<0.05). Similar findings were seen in colorectal cancer patients where increased immunohistochemical expression of filamin A represented an independent prognostic factor together with lymph node metastases and depth of tumor invasion (HR=3.856, 95%CI [7.326:19 . 421], P<0.001). There has been only one study of filamin A protein expression in lung cancer patients, including small cell lung cancer (SCLC). This study suggested the possible role of filamin A in angiogenesis [18] . Similar to our study results these authors found that the overall 5-year survival rate for patients with positive and those with negative filamin A expression was 43.7% and 54.9%, respectively (p=0.06). However, univariate and multivariate survival analyses showed no relation with filamin A expression. This difference might be explained by the complexity of their study group and different evaluation method.
In presented study we stratified NSCLC patients into two treatment groups, those with and those without chemotherapy. Interestingly, there was a significant relationship between overexpression of filamin A and worst increased risk of relapse and death ((HR=1.004, 95%CI [1.001:1.008], P=0.017) and (HR=1.005, 95%CI[1.000;1.010], P=0.037)) in patients treated with carboplatine and navelbine, whilst such a relationship was not found for patients who underwent surgical treatment only. This finding further emphasizes the idea that filamin A plays a complex role not only in tumor growth and progression, but it also modulates the chemotherapy response, particularly in patients treated with platinum-based treatment regimens. To the best of our knowledge, this is the first clinical study to examine the relationship between filamin A expression and patient survival in two different treatment groups. However, the results are in accord with findings that suggest an important role of filamin A protein in DNA repair and resistance to cytotoxic drugs, including cisplatin [14, 17, 18] . Based on experimental study results on melanoma cell lines and mouse models, Yue et all. (2012) showed that not only endogenous levels filamin A reflect the chemosensitivity of tumor cells and not only it can help for the prediction of treatment response, but also filamin A might be used as a therapeutic target to sensitise cells to DNA damaging chemotherapy [14] . Our study also supports this finding, however more in vitro and in vivo experiments on NSCLC are necessary. Also, an extended imunohistochemical study with different filamin A antibodies would be desirable.
In conlcusion, our study results suggest that filamin A expression may represent an important prognostic marker for NSCLC progression and might help to predict platinum-based treatment response.
